evipedia.ai
← Back

Combining Dasatinib & Quercetin as a Senolytic Therapy

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: D+Q, DQ, Dasatinib, Sprycel, BMS-354825, Quercetin, Sophoretin, 3,3’,4’,5,7-pentahydroxyflavone

Motivation

Dasatinib is a prescription cancer medicine and quercetin is a plant compound found in onions, apples and capers. Given together for only a few days at a time, they are the most studied example of a senolytic — a treatment intended to kill off worn-out cells that have stopped dividing but refuse to die, and that leak signals which inflame the tissue around them. These cells accumulate with age, which is why clearing them interests people aiming to lengthen healthy lifespan rather than treat one illness.

The pairing came out of laboratory work in the middle of the last decade showing that each agent kills a different kind of worn-out cell, so the two given together clear more of them than either one alone. Small human studies have since been run in lung scarring, bone loss and memory decline, and a wider set of trials is under way.

This review examines what the combination is, how it is thought to work, what the human and animal evidence shows for and against it, what harms each agent carries on its own, how the reported regimens are built, and what can be measured to follow its effects over time.

Benefits - Risks - Protocol - Conclusion

High-level material that explains the senolytic concept and the dasatinib-plus-quercetin combination in depth, selected across supportive and critical viewpoints.

  • Targeting senescent cells for cognitive health - Kathryn Birkenbach

    A sceptical read of the first Alzheimer’s trial of the combination, explaining what a phase 1 study can and cannot establish and why the biomarker movements were hard to interpret.

  • A Popular Senolytic Treatment Causes Brain Damage in Mice - Anna Barkovskaya

    Plain-language account of the 2026 study reporting that the combination damaged myelin-producing cells in aged mouse brains — the most direct published counterweight to the enthusiasm around this pairing.

  • Improving Brain Aging with Senolytics - Stephen Randall

    Sets the combination inside the broader argument that immune ageing drives brain ageing, and summarises the preclinical case for clearing senescent immune and brain cells.

  • Senolytic drugs: from discovery to translation - Kirkland & Tchkonia, 2020

    Narrative review by the researchers who discovered the combination, laying out the screening logic, the intermittent dosing rationale and the trial programme. Note their institution holds senolytic patents.

  • Senescence - Rhonda Patrick

    Expert overview of cellular senescence that names the combination among identified senolytics and sets it beside diet, exercise, sleep and stress as determinants of senescent-cell burden.

No relevant content was found on hubermanlab.com or chriskresser.com: the Huberman Lab site search for “senolytic” returned only loose keyword matches to unrelated supplement segments, none of which discusses senolytics, and the Chris Kresser site returned only two general articles on nutrition and phytochemicals that never discuss the intervention.

Grokipedia

No Grokipedia article exists for the combination dasatinib and quercetin. The site carries separate articles on the drug class Senolytic and on each agent individually, but no dedicated page for the two used together.

Examine

No Examine article exists for dasatinib and quercetin. Examine.com does not typically cover prescription medications, and dasatinib is a prescription-only tyrosine kinase inhibitor (a drug that blocks the signalling enzymes cells use to relay growth and survival messages), so the combination falls outside the site’s scope even though quercetin alone is within it.

ConsumerLab

No ConsumerLab article exists for dasatinib and quercetin. ConsumerLab does not typically cover prescription medications, and dasatinib is a prescription-only drug, so the combination is outside the site’s product-testing remit.

Systematic Reviews

Systematic reviews and meta-analyses bearing on the two agents, since none covers the combination itself.

The trade-off here is senescent-cell clearance against dasatinib’s toxicity, and both sides are represented: the first three papers address the claimed effect and the last two the principal risk. No systematic review or meta-analysis covers the two agents given together.

Mechanism of Action

Damaged cells can enter senescence: they stop dividing but stay alive, secreting the senescence-associated secretory phenotype (SASP, the mix of inflammatory signals a senescent cell releases). They survive through senescent-cell anti-apoptotic pathways (SCAPs, circuits blocking a cell’s self-destruct programme).

Dasatinib inhibits SRC-family and BCR-ABL tyrosine kinases (signalling enzymes that relay growth and survival messages), removing the ephrin-dependent survival signal senescent fat-cell progenitors depend on. Quercetin, a flavonol, inhibits PI3K (an enzyme in a major cell-survival pathway) and BCL-2 family proteins such as BCL-xL (proteins that block cell suicide), killing senescent endothelial and bone-marrow stromal cells. Neither covers every cell type, so the two are combined for an additive, broader kill spectrum, not a synergistic one; because senescent cells take weeks to return, brief courses suffice.

Co-administration has pharmacological consequences. Dasatinib is cleared mainly by CYP3A4 (a liver enzyme that breaks down many drugs) and by FMO-3 and UGT (enzymes tagging drugs for excretion); quercetin inhibits CYP3A4 and the P-glycoprotein and BCRP transporters (pumps that expel drugs from cells), so it can raise dasatinib exposure. Both also blunt platelet clumping, an additive effect on a shared target.

Dasatinib’s half-life is roughly 3–5 hours, it is 96% protein-bound, and it distributes widely but enters cerebrospinal fluid poorly. Plain quercetin is poorly absorbed and conjugated in gut and liver; its conjugates persist 11–28 hours and were undetectable in cerebrospinal fluid.

Competing readings hold that senescent cells also aid wound repair and tumour suppression, so clearing them may subtract as much as it adds.

Historical Context & Evolution

Dasatinib was developed by Bristol Myers Squibb as a second-generation tyrosine kinase inhibitor and approved in 2006 for Philadelphia chromosome-positive chronic myeloid leukaemia (a blood cancer driven by a fused gene), where it is taken continuously at 100 mg daily for years. Quercetin travelled a separate route: it is an ordinary dietary flavonol that reached shelves as an antioxidant and anti-allergy supplement, later promoted for viral illness.

The two converged in 2015. A Mayo Clinic group reasoned that senescent cells must be resisting their own death signals, mapped the survival networks doing so by transcript analysis, and then screened drugs that disable individual nodes of those networks. Dasatinib killed senescent fat-cell progenitors, quercetin killed senescent endothelial cells and mouse marrow stromal cells, and only the pair killed senescent mouse embryonic fibroblasts. In old mice a single dose improved cardiac and vascular function within five days, and repeated dosing delayed frailty in prematurely ageing mice.

That result reframed both compounds: an oncology drug and a supplement became a candidate ageing-protective regimen, and the “hit-and-run” intermittent schedule — days of dosing, weeks off — followed from the observation that the drugs need not be present once the cells are gone.

Opinion has not settled. Human trials from 2019 onward have shown target engagement but have repeatedly missed their clinical endpoints, and a 2026 mouse study reported white-matter damage, so the case is still being argued on both sides rather than closed.

Expected Benefits

For an audience already willing to take an oncology drug off-label on an intermittent schedule, the relevant question is not whether senolytics are promising in principle but which effects have actually been measured in people, and at what evidential grade.

High 🟩 🟩 🟩

Lower Blood Pressure ⭕️ Not Central to Senolytic Therapy

Quercetin lowers blood pressure independently of any senolytic action; the evidence tested quercetin alone. A meta-analysis of seven randomised controlled trials (RCTs — trials that randomly assign participants to treatment or placebo) in 587 people found falls of 3.04 mmHg systolic and 2.63 mmHg diastolic, larger above 500 mg daily. An umbrella review of meta-analyses confirmed the systolic effect but found none on diastolic pressure or lipids. Those trials dosed daily for weeks; senolytic schedules give quercetin on two or three days per cycle, so carry-over is uncertain.

Magnitude: −3.04 mmHg systolic (95% CI −5.75 to −0.33; CI is the confidence interval, the range within which the true effect most likely lies) and −2.63 mmHg diastolic (95% CI −3.26 to −2.01); at 500 mg/day or more, −4.45 mmHg and −2.98 mmHg respectively.

Medium 🟩 🟩

Increased Bone Formation Signal in Postmenopausal Women ⚠️ Conflicted

The largest randomised controlled trial of the combination treated 60 postmenopausal women intermittently for 20 weeks; it was run by the Mayo Clinic group whose institution holds senolytic patents. The bone-formation marker P1NP (procollagen type 1 N-terminal propeptide, released as bone forms) rose 16% against control at two and four weeks, but the primary endpoint — bone resorption — did not change and P1NP normalised by 20 weeks. In the highest-burden third, forearm bone density rose 2.7%. Net reading: a short-lived signal that missed the chosen endpoint.

Magnitude: P1NP +16% versus control at 2 weeks (P = 0.020; P is the probability that a difference this large would arise by chance alone, so smaller values indicate a firmer result) and 4 weeks (P = 0.024), −9% at 20 weeks (P = 0.149); CTX (C-terminal telopeptide of type 1 collagen, a marker of bone breakdown) changed −4.1% on treatment versus −7.7% on control (P = 0.611); in the highest-senescence third, P1NP +34%, CTX −11% at 2 weeks and radius bone mineral density +2.7% at 20 weeks.

Low 🟩

Reduced Senescent Cell Burden in Fat and Skin

In nine people with diabetic kidney disease, three days of the combination cut fat-tissue cells expressing p16 and p21 (proteins that lock damaged cells out of division), reduced skin senescent cells, and lowered circulating inflammatory proteins within 11 days. Open-label, uncontrolled and very small.

Magnitude: Eleven days after a three-day course, fat-tissue cells carrying p16 fell 35% (P = 0.001) and those carrying p21 fell 17% (P = 0.009); skin epidermal p16 and p21 cells fell 20% and 31%; circulating interleukin-1α, interleukin-6 and matrix metalloproteinases 9 and 12 all fell.

Improved Physical Function in Idiopathic Pulmonary Fibrosis ⚠️ Conflicted

Both tested the combination. An open-label trial in 14 people with idiopathic pulmonary fibrosis (IPF — progressive lung scarring) found gains in walking distance, gait speed and chair-stand time; a later placebo-controlled pilot in 12 people found none. Net reading: the gain did not survive a control group.

Magnitude: In the uncontrolled three-week course, six-minute walk distance rose 21.5 m (P = 0.012), four-metre gait speed rose 0.12 m/s (P = 0.024) and chair-stand time fell 2.2 seconds (P = 0.013); the randomised pilot found no meaningful difference between groups.

Improved Cognitive Screening Score in Adults at Risk of Alzheimer’s Disease

Twelve older adults at risk of Alzheimer’s disease took the combination for two days every two weeks over 12 weeks. The average cognitive screening score rose without reaching significance, and reached it only in those starting lowest. Single-arm, no control group.

Magnitude: Montreal Cognitive Assessment (MoCA, a 30-point cognitive screening test) score +1.0 point overall (95% CI −0.7 to 2.7) and +2.0 points (95% CI 0.1 to 4.0) in those with the lowest baseline scores; tumour necrosis factor-alpha fell 3.0% (95% CI −13.0 to 7.1).

Restored Urinary α-Klotho

α-Klotho is a kidney-derived protein that falls with age and disease. Urinary α-Klotho rose in people with idiopathic pulmonary fibrosis after the combination, matching increases in mice. The human data come from one uncontrolled trial with no clinical endpoint attached.

Magnitude: In people with idiopathic pulmonary fibrosis given nine doses over three weeks, urinary α-Klotho rose from 293 to 393 relative to urinary creatinine (P = 0.04), a gain of about a third.

Lowered Fasting Insulin ⚠️ Conflicted ⭕️ Not Central to Senolytic Therapy

The evidence tested quercetin alone; this bears on insulin regulation, not senescent-cell clearance. The umbrella review of meta-analyses found fasting insulin fell, while fasting glucose and calculated insulin resistance did not move. Net reading: an isolated insulin signal with no confirming glycaemic change.

Magnitude: Fasting insulin −1.07 µU/mL (95% CI −1.9 to −0.1), pooled across five meta-analyses of randomised trials; fasting plasma glucose and calculated insulin resistance showed no change, and the certainty of the evidence ranged from very low to moderate.

Speculative 🟨

Extended Post-Treatment Lifespan and Delayed Frailty

In very old mice, brief courses of the combination improved walking speed, endurance and grip strength and lengthened remaining lifespan; earlier work on the same pairing delayed frailty in prematurely ageing mice. Animal work only.

Anti-Inflammatory Immune Shift in Nonhuman Primates

Six monthly two-day courses of the combination in middle-aged monkeys lowered fat-tissue senescence genes, circulating PAI-1 and MMP-9 (proteins senescent cells secrete), and gut-leakiness markers. Animal data only; no human equivalent exists.

Benefit-Modifying Factors

  • Baseline senescent-cell burden: The clearest modifier found so far. In the bone trial, women in the top third for p16 messenger RNA in blood T cells were the only group in which bone formation, resorption and density all moved favourably.

  • Genetic polymorphisms: CYP3A5*3 (a common variant that switches off the CYP3A5 enzyme, which helps clear dasatinib) and ABCB1 variants (affecting the pump that exports dasatinib from cells) alter dasatinib exposure, and so plausibly alter how much senescent-cell killing a fixed dose achieves.

  • Baseline biomarker levels: Higher starting inflammatory signals leave more room to move. In the cognition pilot, falls in tumour necrosis factor-alpha correlated inversely with cognitive gains, and in the blood-pressure trials quercetin worked best in people with raised pressure.

  • Pre-existing health conditions: Every positive human signal so far comes from people with an active senescence-driven disease — lung fibrosis, diabetic kidney disease, osteoporosis, early Alzheimer’s. No trial has shown benefit in healthy adults, so benefit may scale with disease burden.

  • Age: Senescent cells accumulate with age, so older adults start with more to remove. All published participants were 60 or older, and in the very oldest the competing risk is that fewer cells can be spared if clearance is imprecise.

  • Sex-based differences: Benefit data in women come from the bone trial; men are represented only in the small mixed-sex pilots. Oestrogen loss drives senescent-cell accumulation in bone, so a female-specific skeletal benefit is plausible but unconfirmed in men.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Transient Gastrointestinal, Respiratory and Skin Symptoms

Across the human trials of the combination, short courses produced mild-to-moderate stomach upset, cough and breathlessness, bruising and skin irritation, plus headache and fatigue. The open-label and randomised trials both tested the combination itself, as did the cognition pilot. Nothing serious was attributed to the drugs and symptoms cleared between cycles. Most events track dasatinib’s known profile; because these trials were small and mostly open-label, uncommon harms would not have been detected.

Magnitude: In 14 participants over three weeks, 16 respiratory events, 14 skin irritation or bruising events and 12 gastrointestinal events; in the 12-person randomised pilot, 65 non-serious adverse events on the combination versus 22 on placebo.

Fluid Retention and Pleural Effusion

Dasatinib causes fluid to accumulate, most importantly around the lungs (pleural effusion — fluid between the lung and chest wall, causing breathlessness), probably through inhibition of PDGFR (a receptor governing blood-vessel leakiness) and off-target effects on lymphocytes. Evidence is from dasatinib alone at continuous leukaemia doses, and a dose meta-analysis shows the risk is dose-driven. No case has been reported on intermittent senolytic schedules, where cumulative exposure is a small fraction of oncology exposure.

Magnitude: 28% of patients on dasatinib 100 mg once daily over five years, versus 0.8% on imatinib; label frequencies are 21–42% for general fluid retention and 11–24% for pleural effusion; halving the daily dose to 50 mg cut pleural effusion (risk ratio 0.20, 95% CI 0.08 to 0.50; the risk ratio is the treated group’s risk divided by the comparison group’s, so 0.20 means one-fifth the risk).

Myelosuppression

Dasatinib suppresses bone-marrow output, lowering infection-fighting white cells, platelets and red cells (myelosuppression). A network meta-analysis of 17 randomised trials ranked dasatinib the least safe of six tyrosine kinase inhibitors for every blood-count toxicity. Evidence is from dasatinib alone at continuous leukaemia doses; counts recover on interruption, and the small intermittent-dosing trials have not reported clinically significant low counts.

Magnitude: Surface-under-the-cumulative-ranking values for dasatinib 140 mg, where higher means worse, were 97.2% for thrombocytopenia (low platelets), 90.6% for neutropenia (low infection-fighting white cells), 90.3% for anaemia and 87.4% for leucopenia (a fall in white cells of all types); halving the dose from 100 mg to 50 mg cut thrombocytopenia (risk ratio 0.71, 95% CI 0.52 to 0.96).

Bleeding and Impaired Platelet Function

Beyond low counts, dasatinib blocks SRC kinases inside platelets and impairs clumping, so bleeding can occur at normal platelet counts; gastrointestinal bleeding is the commonest serious form. Evidence is from dasatinib alone. Quercetin also inhibits platelet aggregation, so an additive effect is expected on pharmacological grounds, but the randomised placebo-controlled pilot of the combination reported feasibility and tolerability without measuring bleeding on the two together.

Magnitude: Haemorrhage of any type in 11–26% of patients on continuous dasatinib, with central nervous system bleeding in 0.1–1% and fatal gastrointestinal haemorrhage in post-marketing reports; bruising was among the most frequent events in the senolytic trials.

QT Interval Prolongation

Dasatinib lengthens the heart’s electrical recovery time (the QT interval), which in rare cases triggers dangerous rhythms. Risk rises with low potassium or magnesium and with other QT-lengthening drugs. Evidence is from dasatinib alone, pooled across single-arm leukaemia studies; senolytic trials excluded anyone with a corrected QT interval above 450 milliseconds rather than measuring a drug effect.

Magnitude: Across 911 patients in pooled phase II studies, QT prolongation was reported in 9 and a corrected QT interval above 500 milliseconds in 3 (under 1%); the label frequency for electrocardiographic QT prolongation is 0.1–1%.

Medium 🟥 🟥

Sleep Disturbance and Anxiety

In the randomised placebo-controlled pilot of the combination, sleep disturbance and anxiety were disproportionately reported in the treated arm. The evidence tested the combination, but comes from a single 12-person trial with no mechanism established; dasatinib’s label lists insomnia as common and anxiety as uncommon.

Magnitude: 4 of 6 participants on the combination versus 0 of 6 on placebo in a single randomised pilot; label frequencies for dasatinib alone are 1–10% for insomnia and 0.1–1% for anxiety.

Pulmonary Arterial Hypertension

Dasatinib can raise pressure in the lung arteries, causing breathlessness and, if unrecognised, right-heart failure. It usually improves after stopping but often does not fully normalise. Evidence is from a national registry of dasatinib alone at continuous doses; no case has been linked to intermittent senolytic dosing.

Magnitude: Lowest estimated incidence 0.45% among patients exposed to dasatinib in France; of nine registry cases, none reached a normal mean pulmonary artery pressure and two (22%) died during follow-up.

Low 🟥

Rise in Cerebrospinal Fluid Inflammatory Markers

In five people with mild Alzheimer’s disease, 12 weeks of the combination raised spinal-fluid interleukin-6 and glial fibrillary acidic protein (released by activated support cells in the brain), while senescence-related signals trended down. Uncontrolled, five participants, clinical meaning unknown.

Magnitude: Direction is an increase in spinal-fluid interleukin-6 and glial fibrillary acidic protein over 12 weeks, holding in early symptomatic Alzheimer’s disease; the literature reports statistical significance but no effect-size figure for either marker.

Speculative 🟨

Demyelination in Brain White Matter

In aged mice, alternating-week dosing of the combination damaged oligodendrocytes (cells that insulate nerve fibres) and reduced myelin in the corpus callosum, resembling multiple sclerosis. Animal work only; no human signal exists.

Kidney Injury in Already-Damaged Kidneys

A regulatory safety review flagged animal evidence that quercetin can worsen injury in a kidney that is already damaged, and named this a concern for high supplemental doses. No human data support or refute it.

Promotion of Oestrogen-Dependent Tumours

The same safety review flagged animal evidence that quercetin may promote tumour development in oestrogen-dependent tissue. Human studies report no such signal, but none was designed or long enough to detect one.

Impaired Wound Healing and Tissue Repair

Senescent cells contribute to wound closure, liver repair and tumour suppression, so clearing them repeatedly could impair repair. The concern rests on genetic-clearance experiments in mice, not on human data with this combination.

Amplified Dasatinib Exposure from Quercetin

Quercetin inhibits CYP3A4 and the P-glycoprotein and BCRP transporters that clear dasatinib, so co-administration can raise dasatinib levels and magnify its toxicities. The basis is mechanistic only; no trial has measured exposure on the combination.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP3A5*3 carriers and people with reduced-function ABCB1 variants clear dasatinib more slowly, raising peak exposure and plausibly the risk of fluid retention and low blood counts from a standard 100 mg dose.

  • Baseline biomarker levels: A platelet count in the lower half of normal, a low haemoglobin, or an estimated glomerular filtration rate (eGFR — a calculated measure of kidney filtering capacity) below 30 mL/min/1.73 m² each shrink the safety margin.

  • Pre-existing health conditions: Heart failure, prior pleural effusion, pulmonary hypertension, active peptic ulcer, uncontrolled hypertension and liver enzymes above twice normal were all grounds for exclusion in the registered trials, and each maps onto a documented dasatinib harm.

  • Sex-based differences: Women accounted for the only large randomised safety dataset on intermittent dosing and tolerated it well. In leukaemia cohorts, pleural effusion risk tracks age and cardiac history more than sex, and no sex-specific senolytic signal has been reported.

  • Age: Pleural effusion, fluid retention and bleeding all become more frequent with age on continuous dasatinib. At the older end of the target range, reduced kidney and liver clearance and the use of more medications compound this.

Key Interactions & Contraindications

  • Strong CYP3A4 inhibitors: Ketoconazole, itraconazole, clarithromycin, ritonavir and grapefruit juice raise dasatinib levels sharply. Severity: avoid. Consequence: amplified fluid retention, low counts and QT effects. Mitigation: courses are separated from these agents entirely; the registered trials excluded them.

  • Strong CYP3A4 inducers: Rifampin, carbamazepine, phenytoin, phenobarbital and St John’s wort cut dasatinib exposure. Severity: caution. Consequence: loss of senolytic effect without loss of side effects. Mitigation: no dose escalation is validated, so protocols defer dosing rather than compensate.

  • Acid-reducing medication: Proton pump inhibitors (omeprazole, esomeprazole) and H2 blockers (famotidine) raise stomach pH and cut dasatinib absorption. Severity: avoid. Consequence: ineffective dosing. Mitigation: trials required stopping proton pump inhibitors two days before and during dosing; antacids may be separated by two hours.

  • Anticoagulants and antiplatelet drugs: Warfarin, apixaban, heparins, clopidogrel, ticagrelor, prasugrel and aspirin. Severity: absolute contraindication for therapeutic anticoagulation. Consequence: serious bleeding on top of dasatinib platelet inhibition. Mitigation: trials excluded anticoagulated participants and required antiplatelet drugs to be held around dosing days.

  • Over-the-counter analgesics: Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs — ibuprofen, naproxen, diclofenac) add gastric irritation and platelet inhibition. Severity: caution. Consequence: gastrointestinal bleeding. Mitigation: paracetamol is the substitute analgesic on and around dosing days.

  • QT-prolonging medication: Amiodarone, sotalol, citalopram, ondansetron, macrolides and fluoroquinolones. Severity: caution to avoid. Consequence: ventricular arrhythmia. Mitigation: potassium and magnesium are corrected first; the bone trial excluded anti-arrhythmics known to prolong the QT interval.

  • Quinolone antibiotics: Ciprofloxacin, levofloxacin and moxifloxacin. Severity: avoid. Consequence: quercetin competes with quinolones at their bacterial target, potentially blunting the antibiotic, and both prolong the QT interval. Mitigation: trials excluded anyone on quinolones within ten days.

  • Narrow-therapeutic-index substrates: Ciclosporin, tacrolimus, sirolimus, digoxin and some statins, where a small rise causes harm. Severity: caution. Consequence: quercetin inhibits CYP3A4, CYP2C8 (a second liver enzyme that clears many drugs), P-glycoprotein and BCRP, raising their levels. Mitigation: dosing is separated and drug levels monitored.

  • Antiviral combinations: Nirmatrelvir–ritonavir and similar CYP3A4-dependent antivirals. Severity: avoid. Consequence: quercetin may alter their clearance in either direction. Mitigation: senolytic cycles are postponed until the antiviral course is finished.

  • Supplement interactions: Fish oil, high-dose vitamin E, ginkgo, garlic extract, nattokinase and curcumin all inhibit platelet function. Severity: caution. Consequence: additive bleeding risk with dasatinib. Mitigation: they are paused for the dosing days and 48 hours afterwards.

  • Supplements with additive effects: Beetroot powder, magnesium, potassium and hibiscus extract also lower blood pressure; other senolytics (fisetin, luteolin, navitoclax) hit the same survival pathways. Severity: monitor. Consequence: hypotension, or overlapping toxicity. Mitigation: senolytics are not stacked; the bone trial excluded any within six months.

  • Other interventions: Alcohol can provoke headache and facial flushing with quercetin, and senescence-inducing chemotherapy (alkylating agents, anthracyclines, platinum drugs) works against the intervention’s purpose. Severity: caution. Mitigation: alcohol is avoided on dosing days; senolytics are not used alongside active chemotherapy outside a trial.

Populations who should avoid Dasatinib & Quercetin:

  • Pregnancy, attempted conception and breastfeeding — dasatinib is harmful to a developing fetus, and contraception is advised for 30 days after the last dose
  • Active malignancy, including myeloma, outside a supervised trial
  • Heart failure of any New York Heart Association class, and anyone with a history of pulmonary arterial hypertension or right-heart strain on electrocardiogram
  • Corrected QT interval above 450 milliseconds, or uncorrected low potassium or magnesium
  • Estimated glomerular filtration rate below 30 mL/min/1.73 m², or liver enzymes above twice the upper limit of normal
  • Anyone on therapeutic anticoagulation, or with a bleeding disorder, or a platelet count below the normal range
  • Clinically evident fluid retention, current pleural effusion, or an abnormal complete blood count
  • Anyone taking a tyrosine kinase inhibitor already, or drugs that induce cellular senescence
  • Recent surgery or an unhealed wound, given the theoretical impairment of repair

Risk Mitigation Strategies

  • Cardiac screening before the first dose: An electrocardiogram excluding a corrected QT interval above 450 milliseconds and right-heart strain, plus no history of heart failure or pulmonary hypertension, removes the groups in which dasatinib’s cardiac harms concentrate.

  • Blood-count and organ-function screening: A complete blood count, liver enzymes below twice normal and an estimated glomerular filtration rate above 30 mL/min/1.73 m² before starting guard against myelosuppression and against quercetin’s flagged kidney concern.

  • Low total exposure through intermittent dosing: Two or three consecutive days per 14 to 28 days keeps cumulative dasatinib far below the continuous 100 mg daily oncology exposure at which pleural effusion reaches 28%.

  • Holding platelet-affecting drugs and supplements: Aspirin, NSAIDs, fish oil, vitamin E, ginkgo and garlic are held from the day before dosing until 48 hours after, avoiding a stack on dasatinib’s platelet inhibition and bleeding risk.

  • Stopping acid suppression around dosing: Proton pump inhibitors are discontinued two days before and throughout each dosing period, and antacids separated by two hours, so raised stomach pH does not silently abolish dasatinib absorption.

  • Auditing every co-medication for CYP3A4 involvement: Strong inhibitors and inducers, grapefruit juice and narrow-index substrates are removed before each cycle, since quercetin’s own enzyme inhibition compounds these interactions.

  • Surveillance for fluid and breathing changes: Daily weights during and for two weeks after each cycle, with any gain above 2 kg, new breathlessness or ankle swelling triggering assessment for pleural effusion before the next cycle.

  • Electrolyte correction before dosing: Potassium and magnesium in the normal range on each pre-cycle panel reduce the chance that dasatinib’s QT effect becomes clinically relevant.

  • No stacking of senolytics: One agent at a time, with no fisetin, luteolin or navitoclax in the same period, so that any adverse effect can be attributed and overlapping toxicity is not multiplied.

Therapeutic Protocol

  • Standard regimen: Dasatinib 100 mg once daily on two consecutive days, with quercetin 1000–1250 mg once daily on two or three consecutive days beginning the same morning, repeated every 14 to 28 days. Both agents are taken together, orally.

  • Ratio and relative timing: Roughly one part dasatinib to ten or twelve parts quercetin by weight, given simultaneously on day one so that quercetin’s transporter inhibition and dasatinib’s kinase inhibition overlap.

  • Cycle length alternatives: Trials have used three consecutive days weekly for three weeks, two days every two weeks for twelve weeks, and two to three days every 28 days for twenty weeks. None has been shown superior.

  • Who popularised each approach: The Mayo Clinic group of James Kirkland and Tamara Tchkonia originated the intermittent schedule; the University of Texas Health Science Center at San Antonio and Hebrew SeniorLife ran the two-weekly cognition protocols.

  • Competing approach — single-agent senolytics: Fisetin alone, roughly 20 mg/kg daily for three consecutive days monthly, is the main alternative, avoiding dasatinib entirely at the cost of weaker evidence for clearing fat-cell progenitors.

  • Competing approach — senomorphics: Rather than killing senescent cells, agents such as rapamycin or metformin aim to silence their inflammatory output continuously. Neither framing has outperformed the other on a clinical endpoint.

  • Best time of day: Morning dosing is used throughout the trials, which keeps stomach-upset and any sleep disturbance within waking hours; the randomised pilot found sleep disturbance concentrated in the treated arm.

  • Half-life: Dasatinib clears in about 3–5 hours and quercetin conjugates in 11–28 hours, so both are essentially gone within two days — the basis for the intermittent, drug-free-interval design.

  • Single versus split dosing: Both agents are given as a single daily dose in every published protocol; quercetin has been split morning and evening in some supplement studies, but no senolytic trial has tested splitting.

  • Genetic polymorphisms: CYP3A5*3 and ABCB1 variants change dasatinib exposure enough to matter in leukaemia dosing. No pharmacogenetic dose adjustment has been validated for senolytic use, so genotype currently informs caution rather than dose.

  • Sex-based differences: The only trial large enough to judge dosing enrolled women exclusively, at the same 100 mg dose used in mixed-sex pilots. No sex-specific dose has been established.

  • Age considerations: Every published participant was 60 or older, and the same dose was used throughout. At the older end, reduced clearance argues for the longest dosing interval and the fewest consecutive days.

  • Baseline biomarker levels: Response tracked senescent-cell burden in the bone trial, where only the top third by T-cell p16 responded. Measuring that burden first is the only evidence-based way to select likely responders.

  • Pre-existing health conditions: Kidney disease, lung fibrosis, osteoporosis and early cognitive impairment were the settings in which effects appeared. In people without such a condition, no response has been demonstrated at any dose.

Discontinuation & Cycling

  • Not a continuous therapy: The design is inherently intermittent — short courses with long drug-free intervals — so there is no state of chronic exposure to come off, and cycles can simply stop after any completed course.

  • Stopping the two agents: Both are stopped together at the end of each cycle. Quercetin may be continued alone as an ordinary supplement without dasatinib, but continuing dasatinib without quercetin narrows the range of cells targeted.

  • Withdrawal effects: None have been reported. Because neither agent is present between cycles, there is no physiological dependence and no rebound described in any published trial.

  • Tapering: No taper applies. Dasatinib and quercetin are cleared within about two days, and each cycle already ends abruptly by design.

  • Cycling for continued efficacy: Cycling is the regimen, not an option. Senescent cells take weeks to months to reaccumulate, which is what makes repeated short courses rather than daily dosing the rational schedule.

  • When to stop altogether: New breathlessness, weight gain from fluid, unexplained bruising or bleeding, or a falling blood count are each grounds to stop and not resume until assessed.

Sourcing and Quality

  • Dasatinib is prescription-only: Obtained legitimately only by prescription, as branded Sprycel or a generic. Generic dasatinib is widely available from regulated manufacturers; online sources selling it without a prescription carry no assurance of identity or content.

  • Dasatinib formulation: Film-coated tablets of 20, 50, 70, 80, 100 and 140 mg. The 100 mg tablet is what the senolytic trials used; splitting tablets is unnecessary and disturbs the coating.

  • Quercetin purity is a real problem: Independent testing has repeatedly found supplements containing far less quercetin than labelled, and no regulator verifies content before sale. Third-party verification is not optional here.

  • What to look for in quercetin: A certificate of analysis, third-party seals such as NSF, USP or Informed Choice, and a stated botanical source. Trials specified quercetin phytosome from Sophora japonica leaf complexed with sunflower phosphatidylcholine.

  • Form matters for absorption: Plain quercetin is poorly absorbed. Phytosome and enzymatically modified isoquercitrin forms achieve higher plasma levels at the same nominal dose, which is why trials specified the phytosome.

  • Compounding pharmacies: Not required for either agent. Dasatinib comes in fixed commercial strengths and quercetin in capsules; compounding introduces potency uncertainty without solving any sourcing problem.

Practical Considerations

  • Time to effect: Senescent-cell markers in fat and skin fell within 11 days of a three-day course, and bone formation markers moved by two weeks. Functional changes, where seen at all, took three to twelve weeks.

  • Common pitfall — treating it as a daily drug: Continuous dasatinib is what produces pleural effusion in 28% of leukaemia patients. The intermittent schedule is the safety mechanism, not an inconvenience to be optimised away.

  • Common pitfall — unverified quercetin: Taking a product that assays far below label means dosing dasatinib essentially alone, with its full toxicity and half the intended cell coverage.

  • Common pitfall — ignoring acid suppression: Continuing a proton pump inhibitor through dosing days can abolish dasatinib absorption, leaving an apparently completed course that delivered nothing.

  • Common pitfall — stacking senolytics: Combining this pairing with fisetin or navitoclax multiplies unquantified risk without any evidence of added benefit, and makes attribution of side effects impossible.

  • Regulatory status: Dasatinib is approved only for Philadelphia chromosome-positive leukaemias; senolytic use is entirely off-label. Quercetin is regulated as a dietary supplement, so it is not assessed for efficacy before sale.

  • Cost and accessibility: Generic dasatinib has cut the price sharply, but off-label use is not reimbursed. No insurer or national health system covers senolytic prescribing, and public and philanthropic bodies fund the trials, so payer cost incentives do not shape this literature.

  • Access requires a willing prescriber: The practical barrier is not price but finding a physician prepared to prescribe an oncology drug off-label; in the published protocols, baseline screening and monitoring were settled before any supply was arranged.

Interaction with Foundational Habits

  • Sleep: Direct and potentially blunting. The randomised pilot found sleep disturbance and anxiety concentrated in the treated arm, and dasatinib’s label lists insomnia as common. Morning dosing and avoiding caffeine on dosing days are the practical responses; sleep normally returns between cycles, so cycles can be timed away from demanding weeks.

  • Nutrition: Direct and potentiating for absorption. Quercetin is a fat-soluble flavonol absorbed better with a meal containing fat, and the phytosome form exists for this reason. Grapefruit juice inhibits the enzyme clearing dasatinib, and trial protocols excluded it. Dietary quercetin from onions, capers and apples is nutritionally useful but far below trial doses.

  • Exercise: Indirect and complementary. Exercise independently reduces senescent-cell burden in fat tissue in animal models, so it works towards the same end. No blunting of training adaptation has been reported. Contact sports and heavy loading on dosing days and for 48 hours after carry added bruising and bleeding risk, given dasatinib’s effect on platelets.

  • Stress management: Indirect. Chronic social stress increases senescence signatures across organs in animals, so unmanaged stress plausibly works against the intervention. The measured interaction runs the other way too: the anxiety reported in the randomised pilot makes the dosing days a poor time for high-demand commitments.

Monitoring Protocol & Defining Success

Baseline testing precedes the first dose and covers what dasatinib and quercetin can each disturb, since a test required by only one agent is still required by the combination. That means a complete blood count, a comprehensive metabolic panel with liver enzymes and kidney function, electrolytes including magnesium, an electrocardiogram, and blood pressure. Where the aim is to select likely responders rather than simply to dose, a measure of senescent-cell burden belongs at baseline too. Ongoing monitoring then follows a defined cadence: the blood count and metabolic panel are repeated about one week after the first cycle, again before each subsequent cycle for the first three cycles, and thereafter every three to six months if cycling continues. Weight, blood pressure and breathing symptoms are checked daily during dosing and for two weeks afterwards. An electrocardiogram is repeated annually, or sooner if a QT-prolonging medication is added.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Platelet count 200–350 × 10⁹/L Dasatinib’s most ranked blood toxicity Below 150 is grounds to defer a cycle; no fasting needed
Absolute neutrophil count 2.0–5.0 × 10⁹/L Detects infection-fighting white-cell suppression Conventional range is 1.5–8.0 × 10⁹/L, so the functional band is narrower; draw with the full blood count; a same-day infection can raise it transiently
Haemoglobin 13.5–15.0 g/dL (men), 12.5–14.5 g/dL (women) Anaemia is a ranked dasatinib toxicity Conventional lower limits are 13.5 and 12.0 g/dL; the functional floor is higher
eGFR Above 80 mL/min/1.73 m² Kidney reserve, given quercetin’s flagged animal kidney signal eGFR is estimated glomerular filtration rate, a calculated measure of kidney filtering; the conventional cut-off is 60, the functional target is higher; below 30 is exclusionary
ALT and AST Below 25 U/L (men), below 20 U/L (women) Liver clearance of both agents ALT is alanine aminotransferase and AST aspartate aminotransferase, enzymes released by stressed liver cells; conventional upper limits run to about 40 U/L, well above the functional target; above twice normal is exclusionary
Potassium 4.0–4.5 mmol/L Low potassium amplifies QT prolongation Conventional range is 3.5–5.0 mmol/L, so a “normal” 3.6 is still below the functional band; avoid a tourniquet held long, which falsely raises the value
Magnesium (RBC) 5.0–6.5 mg/dL Low magnesium amplifies QT prolongation Conventional red-cell range starts near 4.2 mg/dL; the functional floor is higher. Red-blood-cell magnesium reflects stores better than serum
Corrected QT interval Below 440 milliseconds Direct measure of dasatinib’s cardiac effect Measured by electrocardiogram; above 450 was exclusionary in the bone trial
Blood pressure Below 120/80 mmHg Quercetin lowers it; dasatinib can raise it Seated, after five minutes’ rest, away from a dosing day
hs-CRP Below 0.5 mg/L General inflammatory tone, downstream of senescent-cell signalling hs-CRP is high-sensitivity C-reactive protein; conventional cut-off is 3.0 mg/L. Defer if unwell
Interleukin-6 Below 1.8 pg/mL A core senescence-associated secretory protein Best paired with hs-CRP and tumour necrosis factor-alpha; morning draw, fasting
T-cell p16 messenger RNA No established target exists — track change from the individual’s own baseline The only measure that predicted response in a randomised trial Available mainly through research laboratories; a top-third value identified the responders
P1NP and CTX No established target for senolytic use — track change from the individual’s own baseline Bone formation and breakdown, the endpoints of the phase 2 randomised trial Fasting, morning draw; CTX in particular varies with food and time of day
Urinary α-Klotho No established target exists — track change from the individual’s own baseline Proposed marker of whether senescent cells were actually cleared First-void sample; research assay, not clinically standardised

Qualitative markers worth tracking alongside the laboratory panel:

  • Breathlessness on stairs or lying flat, and any new cough — the earliest signal of fluid around the lungs
  • Ankle or facial swelling, and morning body weight
  • Unexplained bruising, nosebleeds, bleeding gums or dark stools
  • Sleep quality and anxiety during and after dosing days
  • Walking speed, chair-stand time and stair tolerance, recorded the same way each quarter
  • Energy levels and cognitive clarity in the two weeks after a cycle, since that is where the reported functional changes appeared

A conservative definition of success is laboratory values unchanged, no fluid or bleeding symptoms, and a measurable fall in the individual’s own senescence marker, rather than a subjective sense of rejuvenation.

Emerging Research

  • SToMP-AD phase 2: NCT04685590 randomises 48 people with early Alzheimer’s disease or mild cognitive impairment, with primary completion in 2028. It is the first adequately controlled test of whether the cognitive signal seen in the open-label pilots survives blinding.

  • Frailty in childhood-cancer survivors: NCT04733534 enrols 110 adult survivors, a population with accelerated senescence from prior chemotherapy. Its size makes it the best-powered look so far at whether senescent-cell clearance changes physical function.

  • Senolytics to Improve Osteoporosis Therapy: NCT06018467 enrols 120 people with age-related bone loss. It directly tests whether the short-lived bone formation signal from the 60-woman trial becomes a density outcome at larger scale.

  • Accelerated ageing in mental disorders: NCT05838560 gives the combination to 40 people with schizophrenia or treatment-resistant depression, conditions marked by early biological ageing, with primary completion in 2027.

  • Fibrotic fatty liver disease: NCT05506488 completed in 2026 with 30 participants, extending the fibrosis question from lung to liver. Results will show whether the negative lung result generalises or was organ-specific.

  • Secondary progressive multiple sclerosis: NCT07270120 plans 30 participants. It is the direct human counterpart to the mouse finding that the combination damages myelin, and could either refute that signal or confirm it.

  • Frailty in HIV: NCT07144293 completed in 2026 with 82 participants, testing physical ability and senescent-cell clearance in a population with premature immune ageing.

  • Cancer combination trials: NCT05724329 added the combination to immunotherapy before surgery in 24 head-and-neck cancer patients; Liu et al., 2025 reported a 33.3% major pathological response rate. Oncology use runs counter to quercetin’s flagged tumour-promotion concern.

  • Biomarker validation could undercut the field: Farr et al., 2025 characterised candidate human senescence biomarkers and found the available measures imperfectly aligned, which would weaken every trial that selects or judges participants by them.

  • Fluid biomarker reanalysis: Garbarino et al., 2025 re-examined the Alzheimer’s phase 1 spinal-fluid data, and the interpretation of the inflammatory rises remains unresolved — a finding that could cut either way.

  • Preclinical counter-evidence: Lombardo et al., 2026 reported oligodendrocyte damage and demyelination in aged mice given the combination on the standard intermittent schedule. If reproduced in a second species it would materially change the risk calculation.

Conclusion

Dasatinib and quercetin together are the most studied attempt to remove worn-out cells from the body, and after a decade the honest position is that the idea has been shown to do something measurable without yet being shown to do something useful. Short courses of the pair reduce markers of worn-out cells in fat and skin and shift several blood proteins linked to them. Beyond that, the human record is a series of small studies whose encouraging results came from designs without a comparison group, and whose one properly controlled trial missed the outcome it was built to test while moving a secondary one briefly.

The safety picture is split. The combination itself, given for two or three days at a time, has produced only mild and passing stomach, chest and skin complaints in the trials so far. The drug half of the pair, taken daily for years at cancer doses, causes fluid around the lungs, low blood counts, bleeding and occasional damage to the lung arteries — harms that the brief schedule is designed to avoid rather than harms it has been shown to avoid. Animal work reporting damage to the brain’s insulating cells is an unresolved warning.

Most of this evidence comes from one research group whose institution holds patents on these drugs, and the compounds come from a pharmaceutical company and a lightly regulated supplement market. For anyone weighing the pairing now, the gap between what has been measured and what is claimed is the central fact.

Top - Benefits - Risks - Protocol